Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intratympanic adenosine A2A receptor ligands for hearing loss pharmacokinetics
ACTRN12621000749808Phase 2Not yet recruiting
- Sponsor
- Eisdell Moore Centre
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in sensorineural hearing loss (SNHL) comparing Istradefylline intratympanic arm with Regadenoson intratympanic arm (2 arms). Primary endpoint: Incidence of adverse events. Planned start Jul 2021; status: not yet recruiting.
02
Drugs
Istradefyllineregadenoson
03
Conditions
sensorineural hearing loss (SNHL)
Beyond the preview
Go deeper on ACTRN12621000749808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621000749808.